AI May Help With MRI Interpretation During Prostate Cancer Detection

Commentary
Video

Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.

CancerNetwork® spoke with Wayne G. Brisbane, MD during Prostate Cancer Awareness Month 2023 about how implementing artificial intelligence (AI) into the clinical landscape may help in detecting prostate cancer more effectively in patients who need to undergo an MRI.

Brisbane, an assistant professor of urology at the University of California, Los Angeles (UCLA) Health, discussed his experiences with a machine learning algorithm called Unfold AI in patients with elevated prostate specific antigen (PSA) levels who need to proceed to an MRI, which his practice often employs in prostate cancer detection. He described how the AI program may be able to elucidate signs of disease in an MRI that are not typically perceptible to the human eye, thereby giving information on how best to manage the tumor.

Transcript:

AI is being used in prostate cancer in a couple of different ways, mostly on the diagnostic side. I use it in men who come in with an elevated PSA, which is our best and most reliable way to screen men for prostate cancer. If you have an elevated PSA—I tell men it’s like a thermometer for your prostate; it goes up for all kinds of reasons—maybe it’s something in the prostate that could just be size or some inflammation, but it could be prostate cancer. [Therefore], we need to figure out exactly what that is for men.

We’re using AI to interpret the MRIs. After a PSA elevation, oftentimes men will get an MRI or a biomarker [assessment]—in my [practice], we use MRI quite a bit. We will use the MRIs, and if it doesn’t look like there’s anything to the naked eye, we’ll have an AI go and take a second look at it. [From there] if there is a lesion on the MRI and we do a biopsy. We’re using a machine learning algorithm called Unfold AI that carefully predicts the location and extent of the tumor. We use that to help us perform treatments.

Recent Videos
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
Sympathomimetic effects related to psilocybin may preclude use among patients with coronary artery disease or those with a high risk of stroke.
Psilocybin-assisted psychotherapy may be integrated into pre-existing behavioral health aspects of comprehensive cancer treatment.
Psilocybin may help address a need for effective medication to aid those who have psychological challenges related to a serious cancer diagnosis.
Related Content